Abstract
Hypoxia-inducible factor-1α/β (HIF-1α/β) is a heterodimeric transcriptional activator that mediates gene expression in response to hypoxia. HIF-1α has been noted as an effective therapeutic target for ischemic diseases such as myocardiac infarction, stroke and cancer. By using a yeast two-hybrid system and a random peptide library, we found a 16-mer peptide named F29 that directly interacts with the bHLH-PAS domain of HIF-1α. We found that F29 facilitates the interaction of the HIF-1α/β heterodimer with its target DNA sequence, hypoxia-responsive element (HRE). The transient transfection of an F29-expressing plasmid increases the expression of both an HRE-driven luciferase gene and the endogenous HIF-1 target gene, vascular endothelial growth factor (VEGF). Taken together, we conclude that F29 increases the DNA-binding ability of HIF-1α, leading to increased expression of its target gene VEGF. Our results suggest that F29 can be a lead compound that directly targets HIF-1α and increases its activity.
| Original language | English |
|---|---|
| Pages (from-to) | 737-742 |
| Number of pages | 6 |
| Journal | BMB Reports |
| Volume | 42 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2009 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- HIF-1α
- Hypoxia
- Peptide library
- VEGF
- bHLH-PAS
Fingerprint
Dive into the research topics of 'The novel peptide F29 facilitates the DNA-binding ability of hypoxia-inducible factor-1α'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver